Agenus (AGEN) Reports Q4 Loss of $0.20/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Agenus Corporate Update and Fourth Quarter & Full Year 2020 Financial Report
March 15, 2021 7:45 AM EDTCompletion of balstilimab BLA filing on target for 1H 2021New clinical data for AGEN1181 to be presented at AACRTIGIT bispecific AGEN1777 IND to be filed in 2Q 2021iNKT cell therapy cancer trials to commence in 1H 2021
LEXINGTON, Mass., March 15, 2021 (GLOBE NEWSWIRE) --  Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today provided a corporate update and reported financial results for the fourth quarter and full year... More
